Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Ideal Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$10,523,810

192 payments

Through program year 2025, Ideal Clinical Research is reported as receiving $10,523,810 in research payments, across 192 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $118,557 9
2024 Research $196,377 12
2023 Research $3,830,524 57
2022 Research $4,772,813 65
2021 Research $1,594,465 42
2020 Research $5,000 3
2019 Research $6,073 4

Breakdown

Who paid Research payments · program years 2019–2025
  1. Bavarian Nordic A/S $6,337,808 74 payments
  2. Pfizer Inc. $2,526,368 42 payments
  3. Evofem Biosciences, Inc. $1,044,991 35 payments
  4. Biohaven Pharmaceuticals, Inc. $221,903 4 payments
  5. Sumitomo Pharma America, Inc. $202,306 8 payments
  6. Moderna TX, Inc. $118,557 9 payments
  7. Myovant Sciences Inc. $48,379 11 payments
  8. Biohaven Pharmaceutical Holding Company Ltd. $12,424 2 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $11,073 7 payments
Studies the money was for Research payments · program years 2019–2025
  1. Nct05238025 $3,391,291 28 payments
  2. A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age $2,946,517 46 payments
  3. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $2,515,868 41 payments
  4. Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection $625,552 22 payments
  5. Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection (EVOGUARD) $419,439 13 payments
  6. BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine $234,327 6 payments
  7. A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids Or Endometriosis $182,261 7 payments
  8. A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $118,557 9 payments
  9. Spirit Extension: An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain $43,085 9 payments
  10. Spirit Extension: An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Co-Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain $20,045 1 payment
What the money was spent on Research payments · program years 2019–2025
  1. Professional salary support $979,044 33 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record